Vivimed Labs Meets SEBI Depository Rules for Latest Quarter

Vivimed Labs Ltd has confirmed compliance with SEBI (Depositories and Participants) Regulations, 2018 for the quarter ending March 31, 2026. This confirmation comes via a certificate from its Registrar and Share Transfer Agent (RTA), Aarthi Consultants Private Limited, covering the period from January 1 to March 31, 2026.

Filing Confirms Quarterly Compliance

Vivimed Labs Limited has submitted a compliance certificate to stock exchanges, confirming its adherence to SEBI (Depositories and Participants) Regulations, 2018 for the fourth quarter of fiscal year 2026, which ended March 31, 2026. The certificate was issued by Aarthi Consultants Private Limited, the company's Registrar and Share Transfer Agent (RTA).

Importance of Depository Compliance

Adhering to SEBI (Depositories and Participants) Regulations is vital for the smooth handling of share transfers, dematerialization, and investor services. An RTA's certificate confirms that shareholding records and related processes are managed according to regulatory requirements, which helps build investor confidence.

Company's Regulatory and Financial History

Vivimed Labs, a Hyderabad-based maker of pharmaceuticals and specialty chemicals, has faced significant regulatory and financial challenges recently. Its shares were temporarily suspended from trading, a suspension that was lifted effective December 18, 2025. This followed the company's work to fix previous non-compliance issues under SEBI's Listing Obligations and Disclosure Requirements.

Vivimed Labs has a history of SEBI penalties. In November 2022, it received a Rs 5 lakh fine for insufficient disclosures about its subsidiary's fundraising. In July 2014, SEBI imposed a Rs 10 lakh penalty for failing to disclose dividend payment dates.

Financially, State Bank of India began a forensic audit in March 2022 due to delayed debt payments and the account becoming a Non-Performing Asset (NPA). This led to a debt restructuring proposal. More recently, in February 2026, Vivimed Labs obtained an interim stay from the Telangana High Court regarding CBI proceedings and a bank fraud declaration by SBI. In April 2026, the company also moved out of the 'Large Corporate' classification under SEBI rules, which affected its ability to raise funds.

Implications of the Filing

Confirming compliance with depository rules signals improved operational discipline, a positive sign for the market. This reinforces the company's commitment to regulatory standards, crucial for rebuilding investor trust after past compliance issues and financial difficulties. Consistent adherence to these regulations will be key as Vivimed Labs continues its recovery and operational efforts.

Key Risks to Monitor

While this filing confirms compliance for one quarter, investors will watch for ongoing adherence to all SEBI regulations, particularly given past penalties and disclosure problems. The company's financial health and its progress in ongoing legal proceedings, including the CBI case, remain significant considerations. Vigilance is necessary to prevent a recurrence of issues that led to past trading suspensions or credit downgrades.

Future Monitoring Points

• Continued adherence to SEBI (Depositories and Participants) Regulations and other SEBI disclosure norms.
• Progress on financial recovery and debt management strategies.
• Developments in ongoing legal proceedings, including the CBI case.
• Future quarterly compliance certifications and financial results.